AH Equity Partners Bio I, L.L.C. - Oct 15, 2024 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)

Role
10%+ Owner
Signature
AH Bio Fund I, L.P. for itself and as nominee for AH Bio Fund I-B, L.P., By: AH Equity Partners Bio I, L.L.C., its General Partner, By: /s/ Scott Kupor, Authorized Signatory
Stock symbol
CAMP
Transactions as of
Oct 15, 2024
Transactions value $
$7,999,992
Form type
4
Date filed
10/17/2024, 05:05 PM
Previous filing
Oct 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAMP Common Stock Conversion of derivative security +1.4M 1.4M Oct 15, 2024 By AH Bio Fund I, L.P., as nominee F1, F2
transaction CAMP Common Stock Purchase $2M +182K +13% $11.00 1.58M Oct 15, 2024 By AH Bio Fund I, L.P., as nominee F2
transaction CAMP Common Stock Purchase $6M +545K $11.00 545K Oct 15, 2024 By AH Bio Fund IV, L.P., as nominee F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAMP Series A Prime Preferred Stock Conversion of derivative security -15M -100% 0 Oct 15, 2024 Common Stock 1.34M By AH Bio Fund I, L.P., as nominee F1, F2
transaction CAMP Series B Preferred Stock Conversion of derivative security -679K -100% 0 Oct 15, 2024 Common Stock 60.6K By AH Bio Fund I, L.P., as nominee F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Prime Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
F2 These shares are held of record by AH Bio Fund I, L.P. ("AH Bio I") for itself and as nominee for AH Bio Fund I-B, L.P. AH Equity Partners Bio I, L.L.C. ("AH EP Bio I"), the general partner of AH Bio I, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio I, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio I and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
F3 These shares are held of record by AH Bio Fund IV, L.P. ("AH Bio IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P., and CLF Partners III, LP (collectively, the "AH Bio Fund IV Entities"). AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV"), the general partner of AH Bio IV, may be deemed to have sole power to vote and to dispose of these shares, and Marc Andreessen and Benjamin Horowitz, the managing members of AH EP Bio IV, may be deemed to have shared power to vote and to dispose of these shares. Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of the securities held of record by AH Bio IV and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.